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Abstract
Introduction: Systemic lupus erythematosus (SLE) patients have lower bone mineral density and increased fracture
risk when compared with healthy individuals, due to distinct factors and mechanisms. Bone remodeling is a tightly
orchestrated process dependent on several factors, including the balance between receptor activator of nuclear
factor B ligand (RANKL) and osteoprotegerin (OPG).
Our aim was to assess serum OPG and soluble RANKL (sRANKL) levels as well as sRANKL/OPG ratio in female SLE
patients and compare it with female controls.
Methods: We have evaluated 103 SLE patients and 114 healthy controls, all Caucasian females. All participants
underwent a clinical and laboratory evaluation. sRANKL and OPG were quantified in serum by ELISA based
methods. sRANKL, OPG and sRANKL/OPG ratio levels were compared between SLE patients and age, sex and race
matched healthy controls. For SLE patients, a multivariate analysis was performed, to find the possible predictors of
the changes in sRANKL, OPG and sRANKL/OPG ratio levels.
Results: Although sRANKL levels did not differ between the two groups, serum OPG was lower in SLE patients (P
< 0.001). This led to an increased sRANKL/OPG ratio (P = 0.010) in the patients’ group.
The multivariate analysis was performed considering age and other clinical and laboratorial potential confounders
for these variations in the SLE patients group. We have showed that age (P = 0.001) and levels of anti-Sm
antibodies (P = 0.016) were independent predictors of sRANKL/OPG ratio variations in SLE patients. No relationship
with therapy or disease activity measured by SLEDAI2K was found.
Conclusions: These results are suggestive of increased osteoclastic stimuli driven by the SLE disease mechanisms.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic, multi-
systemic disease of unknown etiology characterized by
chronic inflammation and damage to various organs and
systems due to the production of autoreactive cells and
antibodies [1-3].
SLE patients have lower bone mineral density (BMD)
when compared with healthy individuals and are at
increased risk of fracture [4-7]. Although corticosteroid
exposure is a major contributor to bone loss in SLE
[4,5,8]. disease activity and associated co-morbidities
may contribute to this process [5,8]. In addition, vitamin
D deficiency is a common finding among SLE patients,
further contributing to impaired bone health [5].
Bone remodeling is a tightly orchestrated process in
which osteoclasts attach to the bone surface and remove
bone. After resorption, osteoblasts migrate into the lacu-
nae and produce new bone, which then mineralizes
[3,9]. Expression of the receptor activator of nuclear fac-
tor B ligand (RANKL) by osteoblasts is essential to
osteoclastogenesis. Osteoprotegerin (OPG) is a soluble
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action. Therefore, the RANKL/OPG ratio is critical for
the control of bone resorption [10-12]. Increased
RANKL/OPG ratio has been described in autoimmune
diseases, such as rheumatoid arthritis, and was asso-
ciated with an increased bone loss [7,13,14]. Taking
these arguments into consideration, we have hypothe-
sized that a RANKL/OPG imbalance is also present in
SLE patients.
In the present work we aimed to assess the RANKL/
OPG balance in SLE patients by quantifying serum OPG
and sRANKL levels and their ratio in SLE patients and
healthy controls. Additionally, in SLE patients we have
looked at predictors of serum levels of these proteins
and having as covariates disease features, co-morbidities
and medications.
Materials and methods
Patients
Consecutive Portuguese Caucasian SLE women were
recruited from the rheumatology outpatient clinics of
Hospital de Santa Maria, Lisbon and Hospital Garcia de
Orta, Almada, Portugal. All enrolled patients fulfilled
the classification criteria of the American College of
Rheumatology for SLE (1997) and had normal renal
function defined as serum creatinine < 1.5 mg/dl. A
control group matched to age, sex and race was also
recruited, and was composed of healthy Caucasian
female volunteers, who had not been diagnosed with
SLE, nor had any inflammatory or bone disease and
were not receiving corticosteroids or other medications
known to interfere with bone metabolism. In this study,
103 SLE patients and 114 healthy controls were
enrolled. This study was approved by the local Ethics
Committees and all participants signed a written
informed consent.
All participants underwent a standardized clinical and
laboratory evaluation [15]. Information about age,
height, weight, body mass index (BMI), smoking habits,
alcohol intake, menopause, co-morbidities (hypertension,
hyperlipidemia, diabetes mellitus, hypo or hyperthyroid-
ism) and medication was collected.
For SLE patients, information considering age at dis-
ease diagnosis, disease duration, cumulative clinical
manifestations, presence of autoantibodies, current dis-
ease activity (evaluated using the Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI2K)
[16]), and cumulative damage (scored in accordance to
the Systemic Lupus International Collaborating Clinics/
ACR Damage Index (SLICC) [17]) were also obtained.
Laboratorial determinations
A blood sample was collected from all subjects for mea-
surement of erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), lipids (total cholesterol, HDL,
LDL and tryglicerides), and anti-dsDNA and anti-Sm
antibody titers.
Serum was obtained by blood centrifugation at 1,250
g, 10’, at 4°C and then preserved at -80°C until use for
sRANKL and OPG quantification.
sRANKL quantification was performed using the
ampli sRANKL human ELISA (Immunodiagnostic Sys-
tems, Boldon, UK). OPG was quantified using the
Bender MedSystems (Vienna, Austria) bead-based assay
for quantitative detection of soluble human analytes by
flow cytometry. Both protocols were performed accord-
ing to the manufacturer’s instructions.
Statistical analysis
For statistical purposes samples undetectable or below
the limit of detection (LOD) were considered to have
the lower LOD value supplied by the manufacturer.
Results were reported as means (standard deviation),
medians (interquartile range) for continuous or propor-
tions for categoric variables. sRANKL and OPG levels
and sRANKL/OPG ratio were compared between SLE
patients and healthy controls groups using the non-
parametric Mann-Whitney test.
Subsequently, the impact of demographic parameters,
clinical features, therapeutics and disease characteristics
on these proteins and their ratio was investigated for
SLE patients using univariate followed by multivariate
linear regression analyses. All variables related to the
studied outcome in univariate analyses at a P-value <
0.05 were considered potential predictors and entered in
multivariate linear regression models. The selection of
covariates was stepwise by backward selection, according
to the level of significance. Before performing regression
analysis, sRANKL, OPG, and sRANKL/OPG ratio were
logarithmically transformed for approximation to nor-
mality and to approximate the residuals to the normality
in multiple linear regressions.
Statistical calculations were performed using Statistical
Package for the Social Sciences (SPSS) Statistics Soft-
w a r e ,v . 1 5 . 0( S P S SI n c . ,C h i c a g o ,U S A )a n dat w o - t a i l e d
P-value < 0.05 was selected as significant.
Results
A total of 103 SLE patients and 114 healthy controls
with comparable baseline demographic characteristics
and co-morbidities were studied (Table 1). SLE patients
had a mean age at disease diagnosis of 35.6 ± 14.4
(range 9.0 to 80.0) years, 8.2 ± 6.6 (range 0.2 to 34.2)
years of disease duration, a mean SLEDAI2K of 3.5 ±
4 . 5( r a n g e0t o2 1 )a n daS L I C Cd a m a g es c o r eo f0 . 8±
1.4 (range 0 to 8). A total of 60.2% of the patients were
currently receiving corticosteroids in a mean daily dose
of 12.7 mg.
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groups regarding sRANKL concentration. However, a
statistically significant lower value was found for OPG
levels in SLE patients (P < 0.001) compared to healthy
controls. Consequently, an increase in sRANKL/OPG
ratio (P = 0.010) was found in SLE patients compared to
the healthy control group (Table 2).
The adjusted relationship between demographic para-
meters, clinical features, therapies and disease character-
istics with sRANKL, OPG and sRANKL/OPG ratio was
further analyzed in SLE patients (Table 3).
In univariate analysis, age, BMI, menopausal status,
age at disease onset, the presence of malar rash, and
anti-Sm and anti-dsDNA antibody quantifications were
significantly associated with sRANKL levels. These pos-
sible predictors were included in a multivariate analysis
and age (b = -0.232, 95% CI -0.043 to -0.004; P =
0.017), malar rash (b = 0.243, 95% CI 0.150 to 1.230; P
= 0.013), and levels of anti-Sm antibodies (b = 0.227,
95% CI 0.005 to 0.051; P = 0.018) were identified as
independent predictorso fs R A N K Ll e v e l si nS L E
patients.
The variables associated with OPG levels in univariate
analysis were age, menopausal status, antihypertensive
therapy, diabetes mellitus, triglycerides, age at disease
onset, arthritis and anti-dsDNA titers. All these poten-
tial predictors were included in a multivariate analysis.
Diabetes mellitus (b = 0.247, 95% CI 0.117 to 0.984; P
= 0.013), anti-dsDNA levels (b = -0.239, 95% CI -.004
to 0.000; P = 0.016), and triglycerides (b = 0.306, 95%
CI 0.001 to 0.004; P = 0.002) were found to be indepen-
dent predictors of OPG levels in the serum of SLE
patients.
The same reasoning was applied to the analysis of the
sRANKL/OPG ratio in SLE patients. In the univariate
analysis age, BMI, menopausal status, lipid-lowering
therapy, age at disease onset, the presence of malar rash,
pleuritis and the levels of anti-dsDNA and anti-Sm anti-
bodies came out as possible predictors for changes in
the ratio values. After multivariate analysis age (b =
-0.326, 95% CI -0.055 to -0.015; P = 0.001) and levels of
anti-Sm antibodies (b = 0.229, 95% CI 0.006 to 0.053; P
= 0.016) were independently associated with sRANKL/
OPG ratio levels in SLE patients.
We found no relationship between sRANKL/OPG
ratio and the inflammatory parameters ESR and CRP. In
addition, we found no association between the ratio and
concomitant medications, such as methotrexate, cyclo-
phosphamide, mycophenolate mofetil or azathioprine.
Furthermore, there was also no correlation with corti-
costeroids (use or actual dose) or disease activity mea-
sured by the SLEDAI2K with this ratio.
Although the studied SLE patients presented a wide
range of disease duration, this variable did not come out
as a predictor of sRANKL, OPG or SRANKL/OPG
levels.
Discussion
The present work provides evidence of increased pro-
osteoclastogenic stimuli in SLE women as a result of
decreased serum OPG levels and increased sRANKL/
OPG ratio.
OPG serum levels were lower in SLE patients than in
controls and these levels were negatively associated with
anti-dsDNA levels, independently from the contribution
of multiple confounders. Raised anti-dsDNA levels are
associated with active disease, suggesting that patients
with active SLE might be more exposed to the effect of
RANKL/RANK interaction as a consequence of dimin-
ished OPG levels. We have also found a positive associa-
tion between serum OPG levels and diabetes mellitus,
which is in accordance with previous results [18,19].
Gannagé-Yared and colleagues found an inverse correla-
tion between OPG and triglycerides levels, in a nondia-
betic, elderly Lebanese male population [20]. Although
in a different population, this relation was not
Table 1 SLE patients and healthy controls characteristics
SLE patients Healthy controls P-value
n 103 114 -
Age, years 44.9 ± 14.1 47.4 ± 13.5 0.182
BMI, Kg/m
2 26.6 ± 4.9 26.8 ± 4.9 0.689
Current smokers, n (%) 14 (15.6%) 23 (22.1%) 0.246
Alcohol intake, n (%) 4 (3.9%) 4 (3.6%) 0.602
Postmenopausal, n (%) 44 (49.4%) 57 (53.3%) 0.593
Arterial hypertension, n (%) 52 (50.5%) 47 (42.7%) 0.257
Hyperlipidemia, n (%) 66 (64.1%) 66 (60.6%) 0.596
Diabetes mellitus, n (%) 5 (4.9%) 8 (7.2%) 0.472
Values represent mean ± standard deviation or frequencies of the individuals
that presented the characteristic. Differences were assessed using T-test for
continuous variables or c
2 or Fisher’s exact test for proportions.
BMI, body mass index; SLE, Systemic Lupus Erythematosus
Table 2 sRANKL, OPG and sRANKL/OPG ratio levels in SLE
patients and healthy controls
SLE patients Healthy controls P-
value
sRANKL 0.40 (0.02 to 25.99) 0.40 (0.29 to 67.64) 0.372
OPG 69.02 (17.42 to
500.90)
95.14 (1.56 to
1069.13)
< 0.001
sRANKL/OPG
ratio
0.0103 (0.001 to
0.817)
0.0056 (0.000 to
1.866)
0.010
Values represent median (IQR). Differences were assessed by non-parametric
Mann-Whitney U test.
In 49.5% of SLE patients and 63.2% of healthy controls, the sRANKL levels
were below the limit of detection (LOD) of the quantification method.
Regarding OPG quantification, there were no samples with concentrations
below the LOD.
IQR, interquartile range; OPG, osteoprotegerin; SLE, Systemic Lupus
Erythematosus; sRANKL, soluble RANKL
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relation between serum OPG and triglycerides.
Serum OPG levels have been scarcely analyzed in the
context of SLE. There is a single study reporting higher
serum OPG levels in SLE patients, and this relation is
even greater in patients with antiphospholipid syn-
drome, as OPG levels were related to the presence of
antiphospholipid antibodies [21]. This relation between
OPG and these antibodies was not confirmed by us
(data not shown).
On the other hand, urinary OPG levels have been
described to be raised in lupus nephritis and correlated
with renal disease activity and anti-dsDNA levels
[22,23]. However, at this moment it is not clear how
Table 3 Predictors of sRANKL, OPG and sRANKL/OPG ratio levels in SLE patients (after multivariate analysis)
Possible predictors log(sRANKL) log(OPG) log(sRANKL/OPG ratio)
Univariate analysis Multivariate
analysis
‡
Univariate analysis Multivariate
analysis
§
Univariate analysis Multivariate
analysis*
b coefficient
(95% CI)
b coefficient
(95% CI)
b coefficient
(95% CI)
b coefficient
(95% CI)
b coefficient
(95% CI)
b coefficient
(95% CI)
P-value P-value P-value P-value P-value P-value
Age -0.304
(-0.049 to -0.012)
-0.232
(-0.043 to -0.004)
0.218
(0.001 to 0.015)
-0.363
(-0.058 to -0.019)
-0.326
(-0.065 to
-0.015)
0.002 0.017 0.027 < 0.001 0.001
BMI -0.249
(-0.126 to -0.016)
-0.211
(-0.123 to -0.005)
0.011 0.033
Menopausal status -0.210
(-1.131 to -0.006)
0.211
(0.003 to 0.439)
-0.274
(-1.379 to -0.200)
0.048 0.047 0.009
Lipid lowering
therapy
-0.214
(-1.451 to -0.068)
0.032
Antihypertensive
therapy
0.217
(0.026 to 0.438)
0.028
Diabetes mellitus 0.271
(0.198 to 1.122)
0.247
(0.117 to 0.984)
0.006 0.013
Triglycerides 0.266
(0.000 to 0.003)
0.306
(0.001 to 0.004)
0.011 0.02
Age at disease onset -0.268
(-0.045 to -0.008)
0.237
(0.002 to 0.016)
-0.335
(-0.054 to -0.016)
0.006 0.016 0.001
Malar rash 0.251
(0.166 to 1.246)
0.243
(0.150 to 1.230)
0.201
(0.019 to 1.178)
0.011 0.013 0.043
Arthritis -0.272
(-0.556 to -0.098)
0.005
Pleuritis -0.197
(-1.555 to -0.010)
0.047
Anti-Sm titers 0.224
(0.003 to 0.051)
0.227
(0.005 to 0.051)
0.264
(0.009 to 0.059)
0.229
(0.006 to
0.053)
0.026 0.018 0.008 0.016
Anti-dsDNA titers 0.204
(0.000 to 0.007)
-0.208
(-0.003 to 0.000)
-0.239
(-0.004 to 0.000)
0.268
(0.001 to 0.009)
0.047 0.043 0.016 0.009
Multivariate analysis results from multiple linear regression analysis. The total explained variance of the model is (‡)R
2 = 0.185, (§) R
2 = 0.237, and (*) R
2 = 0.175.
OPG, osteoprotegerin; SLE, Systemic Lupus Erythematosus; sRANKL, soluble RANKL
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ship between serum and urinary OPG levels is
unknown.
We have found sRANKL levels to be similar between
SLE and healthy control women, but the sRANKL/OPG
ratio was increased in SLE patients as compared to con-
trols at the cost of elevated serum OPG levels in SLE.
Interestingly, malar rash and elevated levels of anti-Sm
autoantibodies, often present in active disease, were
associated with sRANKL serum levels. Moreover, in
multivariate analysis levels of anti-Sm antibodies were
positively associated with sRANKL/OPG ratio. Studies
based on sRANKL are sometimes limited by the high
percentage of patients that have undetectable circulating
levels, due to the fact that the majority of RANKL is
membrane bound. Nevertheless, half of our patients had
detectable levels of sRANKL and, importantly, it was
possible to determine serum OPG levels in all
individuals.
Despite the fact that there are no previous references
in the literature to the possible effect of SLE on
sRANKL and sRANKL/OPG ratio, an imbalance of this
ratio has been described in autoimmune diseases, such
as rheumatoid arthritis [13,24]. This finding may be of
clinical relevance as the increase of the sRANKL/OPG
ratio has been related with increased bone loss in
immune mediated inflammatory diseases [12,25]. The
independent association of the sRANKL/OPG ratio with
anti-Sm autoantibodies and the absence of association
with corticosteroid use or dose are particularly relevant,
as they are suggestive that SLE per se might be impor-
tant in accelerating osteoclastogenesis and consequently,
bone loss.
Conclusions
In summary, we have shown reduced OPG levels and
consequently a raised sRANKL/OPG ratio in female SLE
patients as compared to healthy controls. An association
between anti-dsDNA and OPG levels and between anti-
Sm and sRANKL levels and sRANKL/OPG ratio were
also observed in SLE patients. Taken together, these
observations are suggestive of increased osteoclastic sti-
muli driven by SLE disease mechanisms.
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